Dr. Kavita Patel told CNBC on Tuesday she believes the Food and Drug Administration’s recommendation that states pause the use of Johnson & Johnson’s single-shot Covid vaccine is likely to have lasting impacts on the nation’s efforts to combat the pandemic.
“This is a devastating blow to this J&J vaccine effort in the United States,” said Patel, a primary care physician in Washington who worked on health-care initiatives in the Obama administration while serving as director of policy for the Office of Intergovernmental Affairs and Public Engagement.
In an interview on “Squawk Box,” Patel said the supply of the two-shot vaccines from Pfizer and Moderna won’t be able to quickly make up the demand created by the J&J pause. This will delay U.S. vaccination efforts, she added.
The FDA’s recommendation, issued earlier Tuesday, came after six J&J vaccine recipients in the U.S. developed rare and severe blood-clotting issues.
In a tweet, the U.S. regulator said it’s action was being taken “out of an abundance of caution.”
Click here to read more.